Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries - GBI Research Reports

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries - GBI Research Reports
Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
Published Sep 01, 2011
171 pages — Published Sep 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries, which provides insights into the global respiratory disorders market and market forecast until 2017. The report provides an in-depth analysis of the top seven respiratory disorders indications, which includes asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis. In addition, the report also includes insights into the respiratory disorders R&D pipeline. GBI research analysis estimated that 55% of the revenues are generated by AstraZeneca, GSK, Novartis, Merck, Roche, UCB Inc, Actelion and Takeda. Other companies generate 45% of the revenues in the respiratory disorders therapeutics market. AstraZeneca is the leading company in the respiratory disorders therapeutics market. The large amount of fragmentation in the market provides significant scope for consolidation through mergers and acquisitions. Strategic through acquisition accounted for 53% of the M&A deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis shows that the overall respiratory disorders market for the seven indications asthma, COPD, Pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis was valued at $29.4 billion in 2010. The market is expected to witness a growth at a CAGR of 3% for the forecast period and will reach $36.2 billion by 2017. The moderate rate of growth is attributable to patent expiry of branded products. The top pharmaceutical companies in the respiratory disorders market are companies such as AstraZeneca, GlaxoSmithKline, Merck, Actelion, and Novartis.

Scope

- The report analyzes market characterization, pipeline analysis and key M&A trends in the asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis therapeutics market.
- Data and analysis on the global respiratory disorders market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the respiratory disorders market from 2002-2010 with forecasts to 2017.
- Market data on the therapeutic landscape which covers asthma, COPD, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, allergic rhinitis, cystic fibrosis and bronchitis, including market size, market share and annual cost of therapy, treatment flow algorithm and branded and generic share.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global respiratory disorders therapeutics market which includes companies such as AstraZeneca, GlaxoSmithKline, Merck, Actelion, and Novartis.
- Key M&A activities and licensing agreements that took place from 2005-2011 in the global respiratory disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the respiratory disorders market.
- Develop key strategic initiatives by understanding the key focus areas an

  
Source:
Document ID
GBIHC132MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents310
  List of Tables64
  List of Figures103
Respiratory Disorders Therapeutics Market to 2017 - Introduction132
  GBI Research Report Guidance141
Respiratory Disorders Therapeutics Market to 2017 - Market Overview1510
  Introduction151
  Revenue Forecasts for Respiratory Disorders Therapeutics Market151
    Revenues152
      Revenue Share by Geography172
      Global Generic Share191
    Annual Cost of Therapy201
  Treatment Usage Patterns212
  Drivers and Barriers for Respiratory Disorders Therapeutics Market231
    Drivers for Respiratory Disorders231
      Increase in Smoking Population231
      Depleting Environmental Conditions231
      Increase in Awareness Levels of Disease Progression and Etiology241
      Stable Increase in the Number of Incidences of Respiratory Disorders241
    Barriers for Respiratory Disorders241
      Patent Expirations and Entry of Generics Pose a Serious Problem for Primary Manufacturers241
      Reimbursement Restrictions on Drug Classes For Certain Respiratory Disorder Drug Classes Restricts the Market Growth241
Respiratory Disorders Therapeutics Market to 2017 - Geographical Landscape2514
  The US251
    Revenue251
    Annual Cost of Therapy261
    Treatment Usage Pattern272
  Top Five Countries of Europe291
    Revenue291
      Revenue Share by Country302
    Annual Cost of Therapy321
    Treatment Usage Pattern332
  Japan351
    Revenue351
    Annual Cost of Therapy361
    Treatment Usage Pattern372
Respiratory Disorders Therapeutics Market to 2017 - Therapeutic Landscape3970
  Asthma391
    Introduction391
    Revenue392
      Geographical Segmentation412
      Generic Share431
    Annual Cost of Therapy441
    Treatment Usage Patterns452
    Treatment Flow Algorithm471
    Drivers and Barriers for Asthma481
      Drivers for Asthma481
      Barriers for Asthma491
  COPD501
    Introduction501
    Revenue502
      Geographical Segmentation522
      Generic Share541
    Annual Cost of Therapy551
    Treatment Usage Patterns562
    Treatment Flow Algorithm581
    Drivers and Barriers for COPD591
      Drivers for COPD591
      Barriers for COPD591
  Pulmonary Arterial Hypertension601
    Introduction601
      Pulmonary Arterial Hypertension601
      Pulmonary Venous Hypertension601
      Pulmonary Hypertension Associated With Hypoxemia611
      Pulmonary Hypertension Due To Chronic Thrombotic and/or Embolic Disease611
      Miscellaneous611
    Revenue621
      Geographical Segmentation632
      Generic Share651
    Annual Cost of Therapy661
    Treatment Usage Patterns672
    Treatment Flow Algorithm691
    Drivers and Barriers for Pulmonary Arterial Hypertension701
      Drivers for Pulmonary Arterial Hypertension701
      Barriers for Pulmonary Arterial Hypertension701
  Cystic Fibrosis711
    Introduction711
    Revenue712
      Geographical Segmentation732
      Generic Share751
    Annual Cost of Therapy761
    Treatment Usage Patterns772
    Treatment Flow Algorithm791
    Drivers and Barriers for Cystic Fibrosis801
      Drivers for Cystic Fibrosis801
      Barriers for Cystic Fibrosis801
  Allergic Rhinitis811
    Introduction811
    Revenue812
      Geographical Segmentation832
      Generic Share851
    Annual Cost of Therapy861
    Treatment Usage Patterns871
    Treatment Flow Algorithm881
    Drivers and Barriers for Allergic Rhinitis891
      Drivers for Allergic Rhinitis891
      Barriers for Allergic Rhinitis891
  Idiopathic Pulmonary Fibrosis901
    Introduction901
    Revenue901
      Geographical Segmentation912
      Generic Share931
    Annual Cost of Therapy941
    Treatment Usage Patterns952
    Treatment Flow Algorithm971
    Drivers and Barriers for Idiopathic Pulmonary Fibrosis981
      Drivers for Idiopathic Pulmonary Fibrosis981
      Barrier for Idiopathic Pulmonary Fibrosis981
  Bronchitis991
    Introduction991
    Revenue992
      Geographical Segmentation1012
      Generic Share1031
    Annual Cost of Therapy1041
    Treatment Usage Patterns1052
    Treatment Flow Algorithm1071
    Drivers and Barriers for Bronchitis1081
      Drivers for Bronchitis1081
      Barriers for Bronchitis1081
Respiratory Disorders Therapeutics Market to 2017 - Product Pipeline Analysis10928
  Introduction1092
    Research and Development Pipeline - Asthma1116
    Research and Development Pipeline - COPD1174
    Research and Development Pipeline - Pulmonary Arterial Hypertension1212
    Research and Development Pipeline - Cystic Fibrosis1232
    Research and Development Pipeline - Allergic Rhinitis1253
    Research and Development Pipeline - Idiopathic Pulmonary Fibrosis1282
    Research and Development Pipeline - Bronchitis1301
  Profiles of Promising Drugs in the Respiratory Disorders Therapeutics Market1311
    Bilastine1311
      Overview1311
      Efficacy1311
      Safety1311
      Clinical Study Details1311
    Sublivac (Extracts of Allergens)1311
      Overview1311
      Efficacy1321
      Safety1321
      Clinical Study Details1321
    Duonase (Azelastine + Fluticasone)1321
      Overview1321
      Efficacy1321
      Safety1321
      Clinical Study Details1321
    Riociguat1331
      Introduction1331
      Efficacy1331
      Safety1331
      Clinical Study Details1331
    VX-7701331
      Introduction1331
      Efficacy1331
      Safety1341
      Clinical Study Details1341
    Indacaterol1341
      Introduction1341
      Efficacy1341
      Safety1351
      Clinical Trial Details1351
    NVA237 (Glycopyrronium Bromide)1351
      Overview1351
      Efficacy1351
      Safety1351
      Clinical Study Details1351
    Aclidinium Bromide1361
      Overview1361
      Efficacy1361
      Safety1361
      Clinical Study Details1361
Respiratory Disorders Therapeutics Market to 2017 - Competitive Landscape13718
  Market Share Analysis: Respiratory Disorders Market1371
  Drug Profile of Major Marketed Products1381
    Advair Diskus (fluticasone propionate and salmeterol inhalation powder)1381
      Overview1381
      Efficacy1381
      Safety1381
      Clinical Study Details1391
    Symbicort (budesonide/formoterol fumarate dihydrate inhalation aerosol)1401
      Overview1401
      Efficacy1401
      Safety1401
      Clinical Study Details1401
    Singulair (montekeulast sodium)1411
      Overview1411
      Efficacy1411
      Safety1411
      Clinical Study Details1411
    Tracleer1421
      Overview1421
      Efficacy1421
      Safety Profile1421
      Clinical Study Details1431
    Nasonex (mometasone furoate monohydrate)1431
      Overview1431
      Efficacy1431
      Safety1431
      Clinical Study Details1441
  Competitive Profiling1451
    AstraZeneca1451
      Overview1451
      SWOT Analysis1461
    GlaxoSmithKline1471
      Overview1471
      SWOT Analysis1481
    Merck &Co., Inc.1491
      Overview1491
      SWOT Analysis1501
    Actelion1511
      Overview1511
      SWOT Analysis1521
    Novartis1531
      Overview1531
      SWOT Analysis1541
Respiratory Disorders Therapeutics Market to 2017 - M&A Landscape15510
  M&A Landscape1551
    M&A Deals by Year1551
    M&A Deals by Value1561
    M&A Deals by Value ($)1561
    M&A Deals by Geography1571
    M&A Deals by Deal Type1581
    M&A Deals by Deal Sub-Type1591
  R&D Licensing Agreements1601
    Deals by Year1601
    Deals by Geography1611
    Deals by Value ($)1621
    Licensing Agreements by Value ($)1621
  Co-Development Agreements1631
    Deals by Year1631
    Deals by Geography1641
Respiratory Disorders Therapeutics Market to 2017 - Appendix1657
  Market Definitions1651
  Abbreviations1651
  Research Methodology1665
    Coverage1661
    Secondary Research1661
    Primary Research1671
    Section Wise Methodology1671
      Therapeutic Landscape1673
      Geographical Landscape1701
      Pipeline Analysis1701
      Competitive Landscape1701
    Expert Panel Validation1701
  Contact Us1701
  Disclaimer1711
  Sources1711

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries" Sep 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Respiratory-Disorders-Therapeutics-Market-to-2017-Novel-Pipeline-Molecules-such-as-VX-770-and-pirfenidone-May-Offset-Negative-Effect-of-Patent-Expiries-2115-252>
  
APA:
GBI Research Reports. (2011). Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries Sep 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Respiratory-Disorders-Therapeutics-Market-to-2017-Novel-Pipeline-Molecules-such-as-VX-770-and-pirfenidone-May-Offset-Negative-Effect-of-Patent-Expiries-2115-252>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.